Brief: Neovacs Announces Positive Data Review From Last IDSMB Review Prior To Final Results Of Phase IIb Clinical Trial Of Ifnalpha Kinoid In Lupus
13/02/2018 06:00
Feb 13 (Reuters) - Neovacs Sa ALNEV.PA :
* REG-NEOVACS ANNOUNCES POSITIVE DATA REVIEW FROM LAST IDSMB
REVIEW PRIOR TO FINAL RESULTS OF PHASE IIB CLINICAL TRIAL OF
IFNALPHA KINOID IN LUPUS
* NEOVACS SA - FINAL TRIAL RESULTS EXPECTED IN JUNE 2018
Source text for Eikon: ID:nGNE70jbR6
Further company coverage: ALNEV.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Neovacs SA
See all newsBrief: Neovacs And FOCH Hospital Commit To Partnership On Research In Pneumology And Allergology
Brief: Neovacs Presented Latest Results On Its Vaccine Candidates Targeting Allergies
Brief: Neovacs H1 Gross Cash Position Down At EUR 6.2 Mln
Brief: Neovacs: Signature Of Trust Agreement For Equitization Of Bonds Redeemable In Shares With Share Warrants
Brief: Neovacs Launches A Public Offering Of Bonds Redeemable In Shares With Stock Warrants